More News

31 May 2022 GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
24 May 2022 KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
23 May 2022 Innoviva to Acquire Entasis Therapeutics
20 May 2022 Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review
19 May 2022 Almirall and Evotec enter into a multi-target alliance in Medical Dermatology
18 May 2022 BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen
17 May 2022 LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
16 May 2022 AbbVie and Cugene Announce Collaboration in Autoimmune Diseases
16 May 2022 Remix Therapeutics Closes $70 Million Series B Financing
13 May 2022 BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
12 May 2022 Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
11 May 2022 Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
10 May 2022 Pfizer to Acquire Biohaven Pharmaceuticals
09 May 2022 Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression
09 May 2022 OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
04 May 2022 Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
04 May 2022 Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
02 May 2022 Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
01 May 2022 Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
01 May 2022 Biocytogen Enters into Antibody Agreement with Merck KGaA, Darmstadt, Germany
26 Apr 2022 ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
26 Apr 2022 Update on Regulatory Submission for Aducanumab in the European Union
20 Apr 2022 VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders
20 Apr 2022 Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
19 Apr 2022 Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up